# A Study Treating Participants With Early Axial Spondyloarthritis (axSpA) Taking an Intense Treatment Approach Versus Routine Treatment

> **NCT02897115** · PHASE4 · TERMINATED · sponsor: **AbbVie** · enrollment: 22 (actual)

## Conditions studied

- Axial Spondyloarthritis

## Interventions

- **BIOLOGICAL:** Adalimumab
- **OTHER:** Non-steroidal Anti-inflammatory Drugs (NSAIDs)

## Key facts

- **NCT ID:** NCT02897115
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-09-12
- **Primary completion:** 2017-12-21
- **Final completion:** 2017-12-21
- **Target enrollment:** 22 (ACTUAL)
- **Why stopped:** The study was terminated due to slow recruitment.
- **Last updated:** 2019-07-05

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02897115

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02897115, "A Study Treating Participants With Early Axial Spondyloarthritis (axSpA) Taking an Intense Treatment Approach Versus Routine Treatment". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT02897115. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*